Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open continuation trial of H-AL grass pollen oral and sublingual immunotherapy
2004-001521-19Phase 3Completed
- Sponsor
- SEVAPHARMA a.s.
- Start
- Aug 2004
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of H-Al pollens grass mixture I in seasonal allergic rhinitis (SAR) and allergic rhinitis (AR) (2 arms), sponsored by SEVAPHARMA a.s. Primary endpoint: Efficacy. Started Aug 2004; status: completed.
02
Drugs
H-Al pollens grass mixture I
03
Conditions
seasonal allergic rhinitis (SAR)allergic rhinitis (AR)
Beyond the preview
Go deeper on 2004-001521-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001521-19.